Acrivon Therapeutics, Inc. Investing Cash Flow
Acrivon Therapeutics, Inc. (ACRV) reported Investing Cash Flow of $28.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $14.95M, a 23.16% decline year-over-year.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $13.13M, a 31.68% decline year-over-year.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $21.52M, a 49.35% increase year-over-year.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $5.91M, a 63.08% decline year-over-year.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $66.10M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$51.77M, a 202.08% decline from fiscal 2023.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $50.72M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$141.68M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $28.07M 10-Q · filed 2026-08-12 | $49.60M derived: sum of 3 quarters · filed 2026-08-12 | $55.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $13.13M 10-Q · filed 2026-05-13 | $34.65M derived: sum of 2 quarters · filed 2026-05-13 | $40.56M derived: sum of 3 quarters · filed 2026-05-13 | $60.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $21.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $27.43M derived: sum of 2 quarters · filed 2026-03-19 | $46.89M derived: sum of 3 quarters · filed 2026-08-12 | $66.10M 10-K · filed 2026-03-19 |
| 2025-09-30 | $5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $25.36M derived: sum of 2 quarters · filed 2026-08-12 | $44.58M 10-Q · filed 2025-11-13 | $58.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $19.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $38.66M 10-Q · filed 2026-08-12 | $53.08M derived: sum of 3 quarters · filed 2026-08-12 | $69.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $19.21M 10-Q · filed 2026-05-13 | $33.63M derived: sum of 2 quarters · filed 2026-05-13 | $49.64M derived: sum of 3 quarters · filed 2026-05-13 | -$38.41M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $30.42M derived: sum of 2 quarters · filed 2026-03-19 | -$57.62M derived: sum of 3 quarters · filed 2026-03-19 | -$51.77M 10-K · filed 2026-03-19 |
| 2024-09-30 | $16.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$72.03M derived: sum of 2 quarters · filed 2025-11-13 | -$66.18M 10-Q · filed 2025-11-13 | -$45.65M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$88.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$82.19M 10-Q · filed 2025-08-13 | -$61.66M derived: sum of 3 quarters · filed 2025-08-13 | -$60.14M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.85M 10-Q · filed 2025-05-14 | $26.39M derived: sum of 2 quarters · filed 2025-05-14 | $27.90M derived: sum of 3 quarters · filed 2025-05-14 | $47.24M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $20.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $22.05M derived: sum of 2 quarters · filed 2025-03-27 | $41.39M derived: sum of 3 quarters · filed 2025-03-27 | $50.72M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $20.85M derived: sum of 2 quarters · filed 2024-11-13 | $30.18M 10-Q · filed 2024-11-13 | -$64.89M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $19.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $28.66M 10-Q · filed 2024-08-13 | -$66.40M derived: sum of 3 quarters · filed 2024-08-13 | -$111.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $9.33M 10-Q · filed 2024-05-14 | -$85.74M derived: sum of 2 quarters · filed 2024-05-14 | -$130.86M derived: sum of 3 quarters · filed 2024-05-14 | -$131.93M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$95.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$140.19M derived: sum of 2 quarters · filed 2024-03-28 | -$141.26M derived: sum of 3 quarters · filed 2024-03-28 | -$141.68M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$45.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$46.19M derived: sum of 2 quarters · filed 2023-11-09 | -$46.61M 10-Q · filed 2023-11-09 | -$46.75M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.49M 10-Q · filed 2023-08-11 | -$1.63M derived: sum of 3 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$415.00K 10-Q · filed 2023-05-09 | -$552.00K derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$238.00K 10-K · filed 2023-03-28 | ||
| 2021-09-30 | -$101.00K 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |